SERA

Healthcare Medical Devices

Sera Prognostics, Inc.

$2.09

+0.05 +2.45% today

Price History

Not enough data

Key Stats

Market Cap

82.45M

Avg Volume

29,218

EPS

-$0.66

52W High

$3.95

52W Low

$1.56

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-3.91

P/B Ratio

1.39

P/S Ratio

1177.85

EV/EBITDA

-1.07

EV/Revenue

557.22

Margins

Gross Margin (150.0%)

Operating Margin (33346.7%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

76.5%

Return on Equity

(45.0%)

Return on Assets

(23.5%)

Liquidity & Leverage

Current Ratio

1.98

Quick Ratio

1.91

Debt / Equity

0.05

Total Cash

46.45M

Total Debt

3.00M

About

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.